v3.25.1

Related parties (Details) | 12 Months Ended |  |  |
--- | --- | --- | --- | ---
Dec. 31, 2024 EUR (€) employee item | Dec. 31, 2023 EUR (€) item | Dec. 31, 2022 EUR (€) | Dec. 31, 2019 | Nov. 06, 2019 | Aug. 28, 2019
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |
Number of executive committee members | item | 4 |  |  |  |  |
Number of board of directors | employee | 9 |  |  |  |  |
Deferred income other than contract liabilities | € 1,071,352,000 | € 1,327,463,000 | € 1,989,230,000 |  |  |
Gilead [member] |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |
Percentage of ownership interest | 25.35% |  |  | 25.84% | 25.10% | 22.04%
Number of Directors Represented as Board of Directors | item | 2 |  |  |  |  |
Minimum Percentage Of Ownership Required To Appoint Investor Board Designees | 20.00% |  |  |  |  |
Trade and other payables |  | 585,000 |  |  |  |
Trade and other receivables | € 2,268,000 | 5,198,000 | 7,877,000 |  |  |
Royalties Receivable | 2,200,000 | 2,400,000 | 2,600,000 |  |  |
Royalties receivable relating to development of Filgotinib |  | 2,500,000 | 5,100,000 |  |  |
Revenue Recognized Related To The Performance Obligation For The Drug Discovery Platform | 230,182,000 | 230,242,000 | 230,423,000 |  |  |
Revenue Recognised Related To Filgotinib Performance Obligation | 26,041,000 | 429,439,000 | 174,432,000 |  |  |
Royalty income related to the commercialization of filgotinib | 10,604,000 | 9,466,000 | 10,726,000 |  |  |
Cost Reimbursements Recognized Related To The Development Of GLPG1690 | 128,000 | 299,000 | 411,000 |  |  |
Cross charges from and to Gilead relating to filgotinib (4) |  | € 3,643,000 | (2,374,000) |  |  |
included in sales and marketing expenses |  |  | 31,000 |  |  |
Included in research and development expenditure. |  |  | (31,000) |  |  |
Purchase of raw materials, semi-finished products and finished products of Jyseleca |  |  | 13,539,000 |  |  |
Number of performance obligations | item |  | 2 |  |  |  |
Gilead collaboration agreement for drug discovery platform | Gilead [member] |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |
Deferred income other than contract liabilities | € 1,068,981,000 | € 1,299,163,000 | 1,529,405,000 |  |  |
Collaboration agreement for filgotinib | Gilead [member] |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |
Deferred income other than contract liabilities |  | 26,268,000 | € 456,352,000 |  |  |
Revenue That Was Included In Deferred Income At The Beginning Of The Period |  | € 26,300,000 |  |  |  |

X
- Definition The amount of cost reimbursements recognized Related To The Development Of GLPG1690 + References No definition available. + Details
Name: | glpg_CostReimbursementsRecognizedRelatedToDevelopmentOfGlpg1690
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cross charges from and to Gilead relating to filgotinib. + References No definition available. + Details
Name: | glpg_CrossChargesFromAndGileadRelatingToFilgotinib
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of profit share mechanism included in Research and development expenses. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInResearchAndDevelopmentExpenses
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of profit share mechanism costs included in sales and marketing. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInSalesAndMarketingExpenses
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The minimum percentage of ownership interest of Galapagos share capital to appoint investor Board Designees. + References No definition available. + Details
Name: | glpg_MinimumPercentageOfOwnershipRequiredToAppointInvestorBoardDesignees
Namespace Prefix: | glpg_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of board of directors. + References No definition available. + Details
Name: | glpg_NumberOfBoardOfDirectors
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of directors represented or appointed as board of directors. + References No definition available. + Details
Name: | glpg_NumberOfDirectorsRepresentedAsBoardOfDirectors
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of executive committee members. + References No definition available. + Details
Name: | glpg_NumberOfExecutiveCommitteeMembers
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of performance obligations. + References No definition available. + Details
Name: | glpg_NumberOfPerformanceObligations
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership interest. + References No definition available. + Details
Name: | glpg_PercentageOfOwnershipInterest
Namespace Prefix: | glpg_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue Recognised Related To Filgotinib Performance Obligation + References No definition available. + Details
Name: | glpg_RevenueRecognisedRelatedToFilgotinibPerformanceObligation
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognized Related To The Performance Obligation For The Drug Discovery Platform. + References No definition available. + Details
Name: | glpg_RevenueRecognizedRelatedToPerformanceObligationForDrugDiscoveryPlatform
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue that was included in the deferred income balance at the beginning of 2024 and end of 2023. + References No definition available. + Details
Name: | glpg_RevenueThatWasIncludedInDeferredIncomeAtBeginningOfPeriod
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of royalties receivable. + References No definition available. + Details
Name: | glpg_RoyaltiesReceivable
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of royalties receivable relating to development of Filgotinib. + References No definition available. + Details
Name: | glpg_RoyaltiesReceivableRelatingToDevelopmentOfFilgotinib
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2024-01-01 -Paragraph 20 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2024-01-01 -Paragraph 18 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_AmountsPayableRelatedPartyTransactions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2024-01-01 -Paragraph 20 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2024-01-01 -Paragraph 18 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_AmountsReceivableRelatedPartyTransactions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, other than contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DeferredIncomeOtherThanContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of goods purchased by the entity in related party transactions. [Refer: Total for all related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 24 -IssueDate 2024-01-01 -Paragraph 21 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_21_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_PurchasesOfGoodsRelatedPartyTransactions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of income arising from royalties. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RevenueFromRoyalties
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_GileadCollaborationAgreementForDrugDiscoveryPlatformMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |